<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">zdme</journal-id><journal-title-group><journal-title xml:lang="ru">Здоровье мегаполиса</journal-title><trans-title-group xml:lang="en"><trans-title>City Healthcare</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2713-2617</issn><publisher><publisher-name>ГБУ «НИИОЗММ ДЗМ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47619/2713-2617.zm.2024.v.5i3;47-56</article-id><article-id custom-type="elpub" pub-id-type="custom">zdme-63</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCHES</subject></subj-group></article-categories><title-group><article-title>Функциональное восстановление при тяжелых генетических  синдромах: клинический опыт применения клеточной терапии  при синдроме Ангельмана</article-title><trans-title-group xml:lang="en"><trans-title>Functional Recovery in Severe Genetic Syndromes:  Clinical Experience of Cell Therapy in Angelman Syndrome</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7328-5698</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Генералов</surname><given-names>В. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Generalov</surname><given-names>V. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Генералов Василий Олегович – д-р мед. наук, профессор, врач-невролог, эпилептолог, руководитель клиники</p><p>117105, г. Москва, Варшавское ш., д. 13, стр. 2</p></bio><bio xml:lang="en"><p>Vasily O. Generalov – Doctor of Medical Science, Professor, Neurologist, Epileptologist, Head</p><p>13, bld. 2, Varshavskoye shosse, Moscow, 11705</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3371-7537</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ободзинская</surname><given-names>Т. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Obodzinskaya</surname><given-names>T. Ye.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ободзинская Татьяна Евгеньевна – врач-психиатр, психотерапевт, заведующая отделением митохондриальной медицины</p><p>117105, г. Москва, Варшавское ш., д. 13, стр. 2</p></bio><bio xml:lang="en"><p>Tatiana Ye. Obodzinskaya – Psychiatrist, Psychotherapist, Head of Mitochondrial Medicine Department</p><p>13, bld. 2, Varshavskoye shosse, Moscow, 11705</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-7475-2743</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Приказчиков</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Prikazchikov</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Приказчиков Сергей Владимирович – главный специалист организационно-методического отдела по неврологии</p><p>115184, г. Москва, ул. Шарикоподшипниковская, д. 9</p></bio><bio xml:lang="en"><p>Sergey V. Prikazchikov – Chief Specialist of Organizational and Methodological Division for Neurology</p><p>9, Sharikopodshipnikovskaya ul., Moscow, 115088</p></bio><email xlink:type="simple">prikazchikovsv@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4238-5634</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Александренкова</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Aleksandrenkova</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Александренкова Ангелина Николаевна – врач-биохимик</p><p>117105, г. Москва, Варшавское ш., д. 13, стр. 2</p></bio><bio xml:lang="en"><p>Angelina N. Aleksandrenkova – Clinical Biochemist</p><p>13, bld. 2, Varshavskoye shosse, Moscow, 11705</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Клиника «ПланетаМед»</institution></aff><aff xml:lang="en"><institution>Clinic “PlanetaMed”</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научно-исследовательский институт организации здравоохранения и медицинского менеджмента Департамента здравоохранения города Москвы</institution></aff><aff xml:lang="en"><institution>Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>24</day><month>11</month><year>2024</year></pub-date><volume>5</volume><issue>3</issue><fpage>47</fpage><lpage>56</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Генералов В.О., Ободзинская Т.Е., Приказчиков С.В., Александренкова А.Н., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Генералов В.О., Ободзинская Т.Е., Приказчиков С.В., Александренкова А.Н.</copyright-holder><copyright-holder xml:lang="en">Generalov V.O., Obodzinskaya T.Y., Prikazchikov S.V., Aleksandrenkova A.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.city-healthcare.com/jour/article/view/63">https://www.city-healthcare.com/jour/article/view/63</self-uri><abstract><p>Несмотря на значительное развитие медицинских технологий, возможностей лабораторной диагностики и разнообразие таргетных терапевтических инструментов, лечение пациентов с генетической патологией остается значимой проблемой современной медицины. В отсутствие этиопатогенетической терапии пациенты детского возраста с генетическими синдромами получают лишь симптоматическое лечение, направленное на стабилизацию их состояния и нивелирование жизнеугрожающих феноменов, однако не предполагающее даже частичного восстановления функций поврежденных органов. Синдром Ангельмана – редкая и тяжелая генетическая патология, проявляющаяся задержкой психомоторного развития, судорожным синдромом и поведенческими расстройствами, имеющая в целом неблагоприятный прогноз в аспекте развития и социализации пациентов с описываемой генетической аномалией. Трансплантация стволовых клеток – перспективное направление терапевтических воздействий при различных генетических, нейродегенеративных и аутоиммунных заболеваниях. В статье описываются два клинических наблюдения пациентов с верифицированным синдромом Ангельмана, в комплексной терапии которых ключевое место занимала трансплантация стволовых клеток. Результаты комплексного лечения оценивались по данным физикального осмотра, неврологического и психического статуса, нейровизуализационных и функциональных методов исследований, а также результатов лабораторных исследований, в том числе гормонального, митохондриального и иммунного статуса пациентов. В результате лечения оба пациента показали значимый прогресс в психомоторном развитии, динамику лабораторных показателей и данных функциональных исследований, что позволяет рассматривать обсуждаемую комплексную терапию перспективным методом в лечении пациентов даже с тяжелыми генетическими заболеваниями, сопровождающимися значительным поражением нервной системы.</p></abstract><trans-abstract xml:lang="en"><p>Genetic pathologies remain a major challenge in modern medicine, although medical technologies, laboratory diagnostics, and targeted therapy tools have significantly developed and expanded. Since etiopathogenetic therapy is not provided, children with genetic disorders receive only symptomatic treatment stabilizing their status and mitigating life-threatening factors, but not contributing to even a partially functional recovery of damaged organs. Angelman syndrome is a rare and severe genetic pathology characterized by delayed psychomotor development, seizures, and conduct disorders. Patients with this diagnosis have, in general, a poor prognosis for development and socialization. Stem cell transplantation is a promising approach to treating various genetic, neurodegenerative, and autoimmune diseases. The article describes two clinical cases of patients with verified Angelman syndrome who received a combination therapy with stem cell transplantation as a key method. Health outcomes were analyzed using the data of physical examination, assessment of neurological and psychological statuses, testing methods of neuroimaging and functional medicine, and laboratory testing of hormonal, mitochondrial, immune states of patients. The results showed a significant improvement in patients’ psychomotor development and a positive dynamic in laboratory and functional indicators. Therefore, the studied combination therapy approach could become a promising method for treating patients with severe genetic diseases accompanied by serious nervous system damage.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>синдром Ангельмана</kwd><kwd>задержка психоречевого развития</kwd><kwd>стволовые клетки</kwd><kwd>клеточная терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Angelman syndrome</kwd><kwd>delayed mental and speech development</kwd><kwd>stem cells</kwd><kwd>cell therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Sun J. M., Kurtzberg J. Cell therapy for diverse central nervous system disorders: inherited metabolic diseases and autism // Pediatric research. – 2018. – Т. 83. – № 1. – С. 364-371. – doi: 10.1038/pr.2017.254.</mixed-citation><mixed-citation xml:lang="en">Sun J. M., Kurtzberg J. Cell therapy for diverse central nervous system disorders: inherited metabolic diseases and autism // Pediatric research. – 2018. – Т. 83. – № 1. – С. 364-371. – doi: 10.1038/pr.2017.254.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Prasad V. K., Kurtzberg J. Cord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directions // British journal of haematology. – 2010. – Т. 148. – № 3. – С. 356-372. – doi:10.1111/j.1365-2141.2009.07974.x</mixed-citation><mixed-citation xml:lang="en">Prasad V. K., Kurtzberg J. Cord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directions // British journal of haematology. – 2010. – Т. 148. – № 3. – С. 356-372. – doi:10.1111/j.1365-2141.2009.07974.x</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Aslan A., Yuka S. A. Stem Cell-Based Therapeutic Approaches in Genetic Diseases // Cell Biology and Translational Medicine, Volume 20: Organ Function, Maintenance, Repair in Health and Disease. – Cham : Springer Nature Switzerland, 2023. – С. 19-53. – doi: 10.1007/5584_2023_761.</mixed-citation><mixed-citation xml:lang="en">Aslan A., Yuka S. A. Stem Cell-Based Therapeutic Approaches in Genetic Diseases // Cell Biology and Translational Medicine, Volume 20: Organ Function, Maintenance, Repair in Health and Disease. – Cham : Springer Nature Switzerland, 2023. – С. 19-53. – doi: 10.1007/5584_2023_761.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Adhikari A. et al. Functional rescue in an Angelman syndrome model following treatment with lentivector transduced hematopoietic stem cells // Human molecular genetics. – 2021. – Т. 30. – № 12. – С. 1067-1083. – doi: 10.1093/hmg/ddab104</mixed-citation><mixed-citation xml:lang="en">Adhikari A. et al. Functional rescue in an Angelman syndrome model following treatment with lentivector transduced hematopoietic stem cells // Human molecular genetics. – 2021. – Т. 30. – № 12. – С. 1067-1083. – doi: 10.1093/hmg/ddab104</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Baraniak P. R., McDevitt T. C. Stem cell paracrine actions and tissue regeneration // Regenerative medicine. – 2010. – Т. 5. – № 1. – С. 121-143. – doi: 10.2217/rme.09.74.</mixed-citation><mixed-citation xml:lang="en">Baraniak P. R., McDevitt T. C. Stem cell paracrine actions and tissue regeneration // Regenerative medicine. – 2010. – Т. 5. – № 1. – С. 121-143. – doi: 10.2217/rme.09.74.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Stappenbeck T. S., Miyoshi H. The role of stromal stem cells in tissue regeneration and wound repair // Science. – 2009. – Т. 324. – № 5935. – С. 1666-1669. – doi: 10.1126/science.1172687.</mixed-citation><mixed-citation xml:lang="en">Stappenbeck T. S., Miyoshi H. The role of stromal stem cells in tissue regeneration and wound repair // Science. – 2009. – Т. 324. – № 5935. – С. 1666-1669. – doi: 10.1126/science.1172687.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Le Blanc K., Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system // Nature Reviews Immunology. – 2012. – Т. 12. – № 5. – С. 383-396. – doi: 10.1038/nri3209.</mixed-citation><mixed-citation xml:lang="en">Le Blanc K., Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system // Nature Reviews Immunology. – 2012. – Т. 12. – № 5. – С. 383-396. – doi: 10.1038/nri3209.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Yashiro K. et al. Ube3a is required for experience-dependent maturation of the neocortex // Nature neuroscience. – 2009. – Т. 12. – № 6. – С. 777-783. – doi: 10.1038/nn.2327.</mixed-citation><mixed-citation xml:lang="en">Yashiro K. et al. Ube3a is required for experience-dependent maturation of the neocortex // Nature neuroscience. – 2009. – Т. 12. – № 6. – С. 777-783. – doi: 10.1038/nn.2327.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Dindot S. V. et al. The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology // Human molecular genetics. – 2008. – Т. 17. – № 1. – С. 111-118. – doi: 10.1093/hmg/ddm288.</mixed-citation><mixed-citation xml:lang="en">Dindot S. V. et al. The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology // Human molecular genetics. – 2008. – Т. 17. – № 1. – С. 111-118. – doi: 10.1093/hmg/ddm288.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lopez S. J., Segal D. J., LaSalle J. M. UBE3A: an E3 ubiquitin ligase with genome-wide impact in neurodevelopmental disease // Frontiers in molecular neuroscience. – 2019. – Т. 11. – С. 476. – doi: 10.3389/fnmol.2018.00476.</mixed-citation><mixed-citation xml:lang="en">Lopez S. J., Segal D. J., LaSalle J. M. UBE3A: an E3 ubiquitin ligase with genome-wide impact in neurodevelopmental disease // Frontiers in molecular neuroscience. – 2019. – Т. 11. – С. 476. – doi: 10.3389/fnmol.2018.00476.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Sutcliffe J. S. et al. The E6–AP Ubiquitin–Protein Ligase (UBE3A) gene is localized within a narrowed angelman syndrome critical region //Genome research. – 1997. – Т. 7. – № 4. – С. 368-377. – doi: 10.1101/gr.7.4.368.</mixed-citation><mixed-citation xml:lang="en">Sutcliffe J. S. et al. The E6–AP Ubiquitin–Protein Ligase (UBE3A) gene is localized within a narrowed angelman syndrome critical region //Genome research. – 1997. – Т. 7. – № 4. – С. 368-377. – doi: 10.1101/gr.7.4.368.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Cook Jr E. H. et al. Autism or atypical autism in maternally but not paternally derived proximal 15q duplication //American journal of human genetics. – 1997. – Т. 60. – № 4. – С. 928.</mixed-citation><mixed-citation xml:lang="en">Cook Jr E. H. et al. Autism or atypical autism in maternally but not paternally derived proximal 15q duplication //American journal of human genetics. – 1997. – Т. 60. – № 4. – С. 928.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Glessner J. T. et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes // Nature. – 2009. – Т. 459. – № 7246. – С. 569-573. – doi: 10.1038/nature07953.</mixed-citation><mixed-citation xml:lang="en">Glessner J. T. et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes // Nature. – 2009. – Т. 459. – № 7246. – С. 569-573. – doi: 10.1038/nature07953.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Koh S. et al. Human umbilical tissue-derived cells promote synapse formation and neurite outgrowth via thrombospondin family proteins //Journal of Neuroscience. – 2015. – Т. 35. – № 47. – С. 15649-15665. – doi: 10.1523/JNEUROSCI.1364-15.2015.</mixed-citation><mixed-citation xml:lang="en">Koh S. et al. Human umbilical tissue-derived cells promote synapse formation and neurite outgrowth via thrombospondin family proteins //Journal of Neuroscience. – 2015. – Т. 35. – № 47. – С. 15649-15665. – doi: 10.1523/JNEUROSCI.1364-15.2015.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Brinton R. D. Neurosteroids as regenerative agents in the brain: therapeutic implications // Nature Reviews Endocrinology. – 2013. – Т. 9. – № 4. – С. 241-250. – doi: 10.1038/nrendo.2013.31.</mixed-citation><mixed-citation xml:lang="en">Brinton R. D. Neurosteroids as regenerative agents in the brain: therapeutic implications // Nature Reviews Endocrinology. – 2013. – Т. 9. – № 4. – С. 241-250. – doi: 10.1038/nrendo.2013.31.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Li T. et al. Human umbilical cord mesenchymal stem cells: an overview of their potential in cellbased therapy // Expert opinion on biological therapy. – 2015. – Т. 15. – № 9. – С. 1293-1306. – doi: 10.1517/14712598.2015.1051528.</mixed-citation><mixed-citation xml:lang="en">Li T. et al. Human umbilical cord mesenchymal stem cells: an overview of their potential in cellbased therapy // Expert opinion on biological therapy. – 2015. – Т. 15. – № 9. – С. 1293-1306. – doi: 10.1517/14712598.2015.1051528.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Saute J. A. M. et al. Neurological outcomes after hematopoietic stem cell transplantation for cerebral X-linked adrenoleukodystrophy, late onset metachromatic leukodystrophy and Hurler syndrome // Arquivos de Neuro-Psiquiatria. – 2016. – Т. 74. – № 12. – С. 953-966. – doi: 10.1590/0004-282X20160155.</mixed-citation><mixed-citation xml:lang="en">Saute J. A. M. et al. Neurological outcomes after hematopoietic stem cell transplantation for cerebral X-linked adrenoleukodystrophy, late onset metachromatic leukodystrophy and Hurler syndrome // Arquivos de Neuro-Psiquiatria. – 2016. – Т. 74. – № 12. – С. 953-966. – doi: 10.1590/0004-282X20160155.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Musolino P. L. et al. Hematopoietic stem cell transplantation in the leukodystrophies: a systematic review of the literature // Neuropediatrics. – 2014. – С. 169-174. – doi: 10.1055/s-0033-1364179.</mixed-citation><mixed-citation xml:lang="en">Musolino P. L. et al. Hematopoietic stem cell transplantation in the leukodystrophies: a systematic review of the literature // Neuropediatrics. – 2014. – С. 169-174. – doi: 10.1055/s-0033-1364179.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
